Clinical trials: Embryo Transfer
Adenomyosis of Uterus, Implantation Failure
Linzagolix in Adenomyosis and Recurrent Implantation Failure
Adenomyosis is associated with impaired endometrial receptivity and reduced implantation rates in assisted reproduction, even when using high-quality embryos.
- Conditions
- Adenomyosis of Uterus, Implantation Failure, Infertility Female, Embryo Transfer
- Trial name
- LINZA-RIF (NCT07698561)
- Testing
- Linzagolix 200 mg (Yselty)
- Where
- 3 sites in Spain
- Volunteers
- 30 people
- Sponsor
- Vida Fertility Institute
Fertility Issues, Embryo Implantation
Rescue Progesterone Supplementation During Frozen Embryo Transfer
Endometrin is a progesterone supplement prescribed during in vitro fertilization (IVF) for preparation for embryo transfer. The usual dose of Endometrin is 100 mg two to three times per day in the form of an effervescent tablet…
- Conditions
- Fertility Issues, Embryo Implantation, Frozen Embryo Transfer
- Trial name
- P4R (NCT05555121)
- Testing
- Progesterone Effervescent Vaginal Tablet
- Where
- Canada
- Volunteers
- 150 people
- Sponsor
- Clinique Ovo
Embryo Transfer
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Epelsiban in Healthy Female Volunteers
Epelsiban is a potent and selective oxytocin receptor antagonist in development for enhanced implantation rates during in-vitro fertilization (IVF).
- Trial name
- NCT02257359
- Testing
- Epelsiban
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Embryo Transfer
Dose Escalation Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Epelsiban Administered in Repeat Doses in Healthy Women Volunteers
The current study is designed to assess the safety, tolerability and pharmacokinetics (PK) of additional repeat doses of epelsiban in healthy females, and will be the first dosing experience of repeat dosing at higher doses in…
- Trial name
- NCT02703181
- Testing
- Epelsiban (GSK557296)
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Embryo Transfer
Study to Evaluate the Pharmacokinetics, Safety and Tolerability of GSK557296 in Healthy Women Volunteers After Single and Repeat Dosing
GSK557296 is being studied in women for the indication of enhanced embryo and or blastocyst implantation in women undergoing IVF treatment. This study will be the first dosing experience with this compound in women.
- Trial name
- NCT01669083
- Testing
- GSK557296 10 mg, GSK557296 150 mg, GSK557296 dose 3
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Embryo Transfer
A Study to Evaluate Pharmacokinetics, Pharmacodynamics and Tissue Concentrations of Epelsiban
This multi-cohort phase I study is designed to assess the pharmacokinetics (PK) and pharmacodynamics (PD) of oxytocin and to evaluate epelsiban (GSK557296) potential to reduce subendometrial contractractility induced by oxytocin…
- Trial name
- NCT02213029
- Testing
- Epelsiban, Oxytocin, Ortho-Cylcen (21)® tablet
- Where
- 2 sites in United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Luteal Hormone Supplementation in In-vitro Fertilization, Embryo Transfer
Phase 3 Trial to Evaluate the Efficacy and Safety of COL-1620 Vaginal Progesterone Gel
The primary objective of this trial is to demonstrate the non-inferiority of the clinical pregnancy rate per embryo transfer to the historical standard value in in-vitro fertilization (IVF)/embryo transfer (ET) cycles in Japan…
- Trial name
- NCT01863680
- Testing
- COL-1620, Gonadotropin-releasing hormone (GnRH) analogue, Follicle-stimulating hormone (FSH)
- Where
- 5 sites in Japan
- Volunteers
- 178 people
- Sponsor
- Merck KGaA, Darmstadt, Germany